Joseph A Joyce

US Patent:

6908615, Jun 21, 2005

Filed:

Mar 18, 1996

Appl. No.:

08/913644

Inventors:

Kathryn J. Hofmann - Collegeville PA, US
Kathrin U. Jansen - Fort Washington PA, US
Michael P. Neeper - Collegeville PA, US
Joseph G. Joyce - Lansdale PA, US
Hugh A. George - Schwenksville PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K039/12

US Classification:

4242041, 4241861, 4353201, 435 6, 435 691, 4352351, 530300

Abstract:

The present invention is directed to DNA molecules encoding purified human papillomavirus type 18 and derivatives thereof.

US Patent:

6991795, Jan 31, 2006

Filed:

Aug 10, 1999

Appl. No.:

09/762794

Inventors:

Robert S. Lowe - North Wales PA, US
Kathrin U. Jansen - Doylestown PA, US
Joseph G. Joyce - Lansdale PA, US
William L. McClements - Doylestown PA, US
Jessica Ching-Yee Ling - Bensalem PA, US
Michael P. Neeper - Collegeville PA, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12N 7/04
C07K 14/025
A61K 39/12

US Classification:

4241851, 4241861, 4241921, 4242041, 435455, 435456, 4353201, 435325, 435366, 435371, 536 231, 536 2372, 514 2

Abstract:

Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.

US Patent:

7850973, Dec 14, 2010

Filed:

May 1, 2006

Appl. No.:

11/919897

Inventors:

Victor M. Garsky - Blue Bell PA, US
Joseph G. Joyce - Lansdale PA, US
Paul M. Keller - Lansdale PA, US
Gene Kinney - Collegeville PA, US
Xiaoping Liang - Collegeville PA, US
John W. Shiver - Doylestown PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/00
A61K 39/08
A61K 39/095
A61K 39/02
A61K 38/08
A61K 45/00
A61K 33/06

US Classification:

4241851, 42419711, 4242361, 4242471, 4242501, 4241821, 424682, 424698, 4242781, 4242821, 4242831

Abstract:

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

US Patent:

20110014226, Jan 20, 2011

Filed:

Mar 17, 2009

Appl. No.:

12/921890

Inventors:

Michael J. Caulfield - West Point PA, US
Michael D. Miller - Chalfont PA, US
Joseph G. Joyce - Lansdale PA, US
Paul D. Zuck - Trenton NJ, US
Krista L. Getty - Quakertown PA, US
Vadim Dudkin - Lansdale PA, US
Elizabeth A. Ottinger - Harleysville PA, US

International Classification:

A61K 39/385
C40B 30/04
A61K 39/21
A61K 39/29
A61K 39/095
A61K 39/00
C07D 401/12
C07D 211/60
A61P 37/04
A61P 31/18
A61P 31/14
A61P 31/04
A61P 37/02
A61P 29/00
A61P 3/10
A61P 25/00

US Classification:

42419611, 506 9, 4242081, 4242281, 4242501, 42419711, 4241841, 544365, 546189, 546208, 546225

Abstract:

A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the autoimmune disorder.

US Patent:

20110052611, Mar 3, 2011

Filed:

Nov 8, 2010

Appl. No.:

12/907493

Inventors:

VICTOR M. GARSKY - BLUE BELL PA, US
JOSEPH G. JOYCE - LANSDALE PA, US
PAUL M. KELLER - LANSDALE PA, US
GENE KINNEY - BURLINGAME CA, US
XIAOPING LIANG - COLLEGEVILLE PA, US
JOHN W. SHIVER - DOYLESTOWN PA, US

International Classification:

A61K 39/00
A61K 39/395
A61P 25/28
A61P 25/00

US Classification:

4241781, 4241851

Abstract:

The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.

US Patent:

58208704, Oct 13, 1998

Filed:

Mar 22, 1995

Appl. No.:

8/409122

Inventors:

Joseph G. Joyce - Lansdale PA
Hugh A. George - Schwenksville PA
Kathryn J. Hofman - Collegeville PA
Kathrin U. Jansen - Ft. Washington PA
Michael P. Neeper - Collegeville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3902
A61K 3900
C12P 2106
C07K 100

US Classification:

4242041

Abstract:

The present invention is directed to vaccines for human papillomavirus type 18 and derivatives thereof.

US Patent:

61597295, Dec 12, 2000

Filed:

Jan 26, 1998

Appl. No.:

8/913462

Inventors:

Kathryn J. Hofmann - Collegeville PA
Kathrin U. Jansen - Fort Washington PA
Michael P. Neeper - Collegeville PA
Joseph G. Joyce - Lansdale PA
Hugh A. George - Schwenksville PA
E. Dale Lehman - Lansdale PA

Assignee:

Merck & Co., Ltd. - Rahway NJ

International Classification:

C12N 1511
C12N 1581

US Classification:

4353201

Abstract:

The present invention is directed to a synthetic DNA molecule encoding purified human papillomavirus type 11 L1 protein and derivatives thereof.

US Patent:

58210873, Oct 13, 1998

Filed:

Sep 11, 1996

Appl. No.:

8/710082

Inventors:

Robert Lowe - Harleysville PA
Joseph G. Joyce - Lansdale PA
Hugh A. George - Schwenksville PA
Kathryn J. Hofmann - Collegeville PA
Kathrin U. Jansen - Ft. Washington PA
E. Dale Lehman - Lansdale PA
Michael P. Neeper - Collegeville PA

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C12Q 170
C12P 2106
A61K 3921
A61K 3912

US Classification:

435 693

Abstract:

The present invention is directed to a recombinant human papillomavirus type 11 L1 protein encoded by a synthetic DNA molecule and methods of making and using the protein.